These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 22719160)

  • 1. Doxorubicin-induced cardiomyopathy 17 years after chemotherapy.
    Kumar S; Marfatia R; Tannenbaum S; Yang C; Avelar E
    Tex Heart Inst J; 2012; 39(3):424-7. PubMed ID: 22719160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological interventions for preventing anthracycline-induced clinical and subclinical cardiotoxicity: A network meta-analysis of metastatic breast cancer.
    Ghasemi K; Vaseghi G; Mansourian M
    J Oncol Pharm Pract; 2021 Mar; 27(2):414-427. PubMed ID: 33081570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recovery from left ventricular dysfunction was associated with the early introduction of heart failure medical treatment in cancer patients with anthracycline-induced cardiotoxicity.
    Ohtani K; Fujino T; Ide T; Funakoshi K; Sakamoto I; Hiasa KI; Higo T; Kamezaki K; Akashi K; Tsutsui H
    Clin Res Cardiol; 2019 Jun; 108(6):600-611. PubMed ID: 30367208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anthracycline Therapy Is Associated With Cardiomyocyte Atrophy and Preclinical Manifestations of Heart Disease.
    Ferreira de Souza T; Quinaglia A C Silva T; Osorio Costa F; Shah R; Neilan TG; Velloso L; Nadruz W; Brenelli F; Sposito AC; Matos-Souza JR; Cendes F; Coelho OR; Jerosch-Herold M; Coelho-Filho OR
    JACC Cardiovasc Imaging; 2018 Aug; 11(8):1045-1055. PubMed ID: 30092965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversible Cardiomyopathy After Epirubicin Administration.
    Koitabashi N; Ohyama Y; Tateno R; Arai M; Rokutanda N; Horiguchi J; Kurabayashi M
    Int Heart J; 2015; 56(4):466-8. PubMed ID: 26104177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Left ventricular assist device as destination therapy in doxorubicin-induced cardiomyopathy.
    Simsir SA; Lin SS; Blue LJ; Gockerman JP; Russell SD; Milano CA
    Ann Thorac Surg; 2005 Aug; 80(2):717-9. PubMed ID: 16039240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Exogenous Phosphocreatine in Chemotherapy-induced Cardiomyopathy.
    Parve S; Aliakberova GI; Gylmanov AA; Abdulganieva DI
    Rev Cardiovasc Med; 2017; 18(2):82-87. PubMed ID: 29038417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transient Cardiomyopathy and Quadriplegia Induced by Ephedrine Decongestant.
    Snipelisky DF; Kurklinsky AK; Chirila R
    Tex Heart Inst J; 2015 Dec; 42(6):575-8. PubMed ID: 26664316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Appraising cardiotoxicity associated with liposomal doxorubicin by means of tissue Doppler echocardiography end-points: rationale and design of the LITE (Liposomal doxorubicin-Investigational chemotherapy-Tissue Doppler imaging Evaluation) randomized pilot study.
    Lotrionte M; Palazzoni G; Natali R; Comerci G; Abbate A; Di Persio S; Biondi-Zoccai GG
    Int J Cardiol; 2009 Jun; 135(1):72-7. PubMed ID: 18572266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac magnetic resonance imaging for the assessment of the myocardium after doxorubicin-based chemotherapy.
    Lunning MA; Kutty S; Rome ET; Li L; Padiyath A; Loberiza F; Bociek RG; Bierman PJ; Vose JM; Armitage JO; Porter TR
    Am J Clin Oncol; 2015 Aug; 38(4):377-81. PubMed ID: 24192805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis of anthracycline-induced late cardiomyopathy by exercise-spiroergometry and stress-echocardiography.
    Hauser M; Gibson BS; Wilson N
    Eur J Pediatr; 2001 Oct; 160(10):607-10. PubMed ID: 11686505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.
    Lipshultz SE; Scully RE; Lipsitz SR; Sallan SE; Silverman LB; Miller TL; Barry EV; Asselin BL; Athale U; Clavell LA; Larsen E; Moghrabi A; Samson Y; Michon B; Schorin MA; Cohen HJ; Neuberg DS; Orav EJ; Colan SD
    Lancet Oncol; 2010 Oct; 11(10):950-61. PubMed ID: 20850381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of tests for monitoring doxorubicin-induced cardiomyopathy.
    Ganz WI; Sridhar KS; Ganz SS; Gonzalez R; Chakko S; Serafini A
    Oncology; 1996; 53(6):461-70. PubMed ID: 8960141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure.
    Tallaj JA; Franco V; Rayburn BK; Pinderski L; Benza RL; Pamboukian S; Foley B; Bourge RC
    J Heart Lung Transplant; 2005 Dec; 24(12):2196-201. PubMed ID: 16364871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
    Yu AF; Singh JC; Wang R; Liu JE; Eaton A; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
    Oncologist; 2017 Jun; 22(6):642-647. PubMed ID: 28341761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-invasive monitoring of cardiac hemodynamic parameters in doxorubicin-treated patients: comparison with echocardiography.
    Villani F; Meazza R; Materazzo C
    Anticancer Res; 2006; 26(1B):797-801. PubMed ID: 16739356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of N-terminal pro-brain natriuretic peptide to assess left ventricular function after adjuvant doxorubicin therapy in early breast cancer patients: a prospective series.
    Cil T; Kaplan AM; Altintas A; Akin AM; Alan S; Isikdogan A
    Clin Drug Investig; 2009; 29(2):131-7. PubMed ID: 19133708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute cardiomyopathy following a single dose of doxorubicin in a patient with adult T-Cell leukemia/lymphoma.
    Farina K; Kalac M; Kim S
    J Oncol Pharm Pract; 2021 Jun; 27(4):1011-1015. PubMed ID: 32869692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of anthracycline cardiotoxicity: left ventricular ejection fraction is not enough.
    Eidem BW
    J Am Soc Echocardiogr; 2008 Dec; 21(12):1290-2. PubMed ID: 19041570
    [No Abstract]   [Full Text] [Related]  

  • 20. Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity.
    Nabati M; Janbabai G; Baghyari S; Esmaili K; Yazdani J
    J Cardiovasc Pharmacol; 2017 May; 69(5):279-285. PubMed ID: 28141699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.